 Greenwich Lifesciences Inc NASDAQ: GLSI shares are trading higher by more than 15 after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0 metastatic breast cancer recurrences over five years of follow-up. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of immunotherapy to prevent breast cancer recurrences in patients. 